A recent study evaluated the role of CSF-NGS in osimertinib-treated EGFR-mutated NSCLC and found that the detection rate of EGFR mutations using CSF genotyping was 97.1%, compared to 95.5% in our study (35). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.